Who
John E. Friend II
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Kazia Therapeutics; Chief Medical Officer, Cellectar Biosciences.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 17 Apr 2017
- Last trade
- 8 Jan 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jan 2026filed 8 Jul 2026 | KZIA Kazia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 8 Jan 2026filed 8 Jul 2026 | KZIA Kazia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 8 Jan 2026filed 8 Jul 2026 | KZIA Kazia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 8 Jan 2026filed 8 Jul 2026 | KZIA Kazia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 4 Mar 2021filed 5 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 1 Jul 2020filed 6 Jul 2020 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Oct 2018filed 15 Oct 2018 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —63,000 at $0.00 | filing |
| 17 Apr 2017filed 18 Apr 2017 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.